CA3107370A1 - Methods of treatment and prevention of alzheimer's disease - Google Patents
Methods of treatment and prevention of alzheimer's disease Download PDFInfo
- Publication number
- CA3107370A1 CA3107370A1 CA3107370A CA3107370A CA3107370A1 CA 3107370 A1 CA3107370 A1 CA 3107370A1 CA 3107370 A CA3107370 A CA 3107370A CA 3107370 A CA3107370 A CA 3107370A CA 3107370 A1 CA3107370 A1 CA 3107370A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- months
- administration
- composition
- relative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US62/702,659 | 2018-07-24 | ||
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US62/749,614 | 2018-10-23 | ||
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US62/824,162 | 2019-03-26 | ||
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US62/846,902 | 2019-05-13 | ||
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| US62/874,684 | 2019-07-16 | ||
| PCT/US2019/043067 WO2020023530A2 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107370A1 true CA3107370A1 (en) | 2020-01-30 |
Family
ID=67551415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107370A Pending CA3107370A1 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (https=) |
| EP (1) | EP3826674A2 (https=) |
| JP (2) | JP7541505B2 (https=) |
| KR (1) | KR20210039402A (https=) |
| CN (2) | CN118924896A (https=) |
| AU (1) | AU2019309938B2 (https=) |
| BR (1) | BR112021001272A2 (https=) |
| CA (1) | CA3107370A1 (https=) |
| IL (3) | IL280315B2 (https=) |
| MX (1) | MX2021000778A (https=) |
| PH (1) | PH12021500006A1 (https=) |
| TW (1) | TW202019471A (https=) |
| WO (1) | WO2020023530A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| RS67249B1 (sr) * | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
| US20230302009A1 (en) * | 2020-08-12 | 2023-09-28 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| MX2024007288A (es) * | 2021-12-17 | 2024-06-28 | Eisai R&D Man Co Ltd | Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. |
| AU2022439338A1 (en) * | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) * | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| PL2233474T3 (pl) | 2008-01-18 | 2015-12-31 | Eisai R&D Man Co Ltd | Skondensowana pochodna aminodihydrotiazyny |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| US20130084245A1 (en) * | 2010-02-25 | 2013-04-04 | Wyeth Llc | Pet monitoring of a-beta-directed immunotherapy |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| ES2624288T3 (es) | 2011-01-21 | 2017-07-13 | Eisai R&D Management Co., Ltd. | Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados |
| WO2016005466A2 (en) * | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| US20190016791A1 (en) * | 2016-01-20 | 2019-01-17 | Genentech, Inc. | High dose treatments for alzheimer's disease |
| EP3454904B1 (en) * | 2016-05-13 | 2022-12-14 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| BR112019008359A2 (pt) * | 2016-10-27 | 2019-10-01 | Eisai R&D Man Co Ltd | método para tratamento da doença de alzheimer, e, composição farmacêutica. |
-
2019
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt active IP Right Grant
- 2019-07-23 IL IL310132A patent/IL310132B2/en unknown
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 AU AU2019309938A patent/AU2019309938B2/en active Active
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118924896A (zh) | 2024-11-12 |
| EP3826674A2 (en) | 2021-06-02 |
| WO2020023530A3 (en) | 2020-03-12 |
| MX2021000778A (es) | 2021-03-31 |
| IL280315B1 (en) | 2024-02-01 |
| IL323583A (en) | 2025-11-01 |
| PH12021500006A1 (en) | 2021-09-13 |
| BR112021001272A2 (pt) | 2021-04-27 |
| TW202019471A (zh) | 2020-06-01 |
| CN112805031A (zh) | 2021-05-14 |
| IL280315B2 (en) | 2024-06-01 |
| JP7541505B2 (ja) | 2024-08-28 |
| IL310132B2 (en) | 2026-03-01 |
| US20210324056A1 (en) | 2021-10-21 |
| IL280315A (en) | 2021-03-25 |
| AU2019309938B2 (en) | 2026-04-02 |
| AU2019309938A1 (en) | 2021-03-11 |
| WO2020023530A2 (en) | 2020-01-30 |
| IL310132B1 (en) | 2025-11-01 |
| KR20210039402A (ko) | 2021-04-09 |
| JP2024112859A (ja) | 2024-08-21 |
| JP2021532126A (ja) | 2021-11-25 |
| IL310132A (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019309938B2 (en) | Methods of treatment and prevention of Alzheimer's disease | |
| JP2018111723A (ja) | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 | |
| JP2017160178A (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| US20250163135A1 (en) | Biomarkers for alzheimer's disease treatment | |
| WO2023149970A1 (en) | Methods of treatment using p-tau181 level | |
| EP4626918A1 (en) | Methods of treatment using a tau pet level | |
| CA3230148A1 (en) | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof | |
| RU2832167C2 (ru) | Способы лечения и предупреждения болезни альцгеймера | |
| HK40118843A (zh) | 阿尔茨海默病的治疗及预防方法 | |
| CN117999094A (zh) | 抗Aβ初原纤维抗体的皮下配制品及其使用方法 | |
| BR122025003268A2 (pt) | Métodos de tratamento e prevenção de doença de alzheimer | |
| CN118786141A (zh) | 使用p-tau181水平的治疗方法 | |
| TW202518027A (zh) | 抗微生物肽 | |
| TW202513583A (zh) | 使用抗Ａβ初原纖維抗體之治療方法 | |
| CN121263186A (zh) | 用厄达替尼治疗局部晚期或转移性尿路上皮癌 | |
| CN116507637A (zh) | 抗转甲状腺素蛋白抗体及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240719 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240719 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240719 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240722 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240722 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241122 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241122 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250411 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250718 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250718 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260203 |